BioCentury | May 28, 2020
Product Development

May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

EC approves Zeposia ozanimod for relapsing-remitting MS The European Commission approved Zeposia ozanimod from Bristol Myers Squibb Co. (NYSE:BMY) to treat relapsing-remitting multiple sclerosis (RRMS). FDA approved the S1P receptor modulator in March for relapsing...
BioCentury | Apr 3, 2020
Distillery Therapeutics

Depletion of the mitochondrial chaperone HspA9 for BRAF-mutant melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Reducing production of the mitochondrial chaperone HspA9 could treat BRAF-mutant melanoma. In melanoma patients, high tumor levels of HspA9 mRNA were associated with poor survival. In two human melanoma cell...
BioCentury | Nov 21, 2019
Tools & Techniques

Measuring real-time PK/PD by monitoring aberrant chaperone activity

...stress, the protein-protein interaction network core -- which contains co-chaperones and chaperones including Hsp90 and HspA8...
...epichaperome inhibitors for cancer and neurodegenerative diseases. Targets Hsp70 - Heat shock protein 70 HspA8 (HSC70...
BioCentury | Nov 14, 2019
Targets & Mechanisms

New roles for HDACs in the cytoplasm and muscle disorders

...used it to identify new, cytoplasmic HDAC4 substrates -- myosin heavy chain isoforms, PGC-1α and HspA8...
...the substrates' deacetylation. The researchers showed that HDAC4 physically interacted or co-localized with PGC-1α and HspA8...
...on the study. Targets HDAC4 - Histone deacetylase 4 HDAC3 - Histone deacetylase 3 HspA8 (HSC70...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

...folding DNAJ; AR-V7 DNAJ isoforms AR-V7-expressing CRPC 2901 HSPA4 HSP70; AR-V7 HSPA5 AR-V7-expressing CRPC 2901 HSPA8...
BioCentury | Oct 24, 2017
Distillery Therapeutics

Neurology

...INDICATION: Amyotrophic lateral sclerosis (ALS) Mouse and fruit fly studies suggest promoting HspA8 expression could help...
...overexpressing TDP-43 with the ALS-associated point mutations A315T and G298S, respectively, neuromuscular junction levels of HspA8...
...HspA8 expression in additional models of ALS. TARGET/MARKER/PATHWAY: Heat shock 70 kDa protein 8 (HspA8; HSC70...
BioCentury | Oct 13, 2017
Financial News

Intezyne raises $10M in series A

On Oct. 6, Intezyne Technologies Inc. (Tampa, Fla.) raised $10 million in an oversubscribed series A round led by existing investor Gaston Capital Healthcare Fund (GCHF). Undisclosed high-net-worth investors and family offices also participated. CFO...
BioCentury | Oct 6, 2017
Financial News

Intezyne raises $10M series A

Intezyne Technologies Inc. (Tampa, Fla.) raised $10 million in an oversubscribed series A round led by existing investor Gaston Capital Healthcare Fund (GCHF). Undisclosed high-net-worth investors and family offices also participated. CFO E. Russell McAllister...
BioCentury | Aug 17, 2017
Targets & Mechanisms

GRP-THINK AT THE BBB

Biogen Inc. has discovered antibodies in patients with a rare CNS autoimmune disease that could provide a new way to deliver mAbs across the blood-brain barrier, an application with wide-reaching ramifications for neurologic drug development....
BioCentury | Jun 29, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

New Therapeutic Targets and Biomarkers: June 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2017. Therapeutic targets are defined as any protein, gene or other...
Items per page:
1 - 10 of 46